EUCTR2017-001804-31-Outside-EU/EEA进行中（未招募）1 期
Ph3 trial of Glivec in CML-CP patients previously untreated with IFN-alfa
ovartis Pharma K.K0 个研究点目标入组 107 人开始时间: 2017年8月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 107
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Diagnosed as CML-CP, between 15 and 75 years of age, previously untreated with IFN-alfa, performance status is normal or capable of only limited self-care.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 87
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 19
排除标准
- •Patients who are pregnant or possibly pregnant, significant hepatic diseases, CML patients in advanced phase
研究者
相似试验
已完成
4 期
Glivec in Pediatric Chronic Myeloid Leukemia (CML)Chronic Myeloid LeukemiaNCT00845221Poitiers University Hospital44
已完成
4 期
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaChronic Myelogenous LeukemiaNCT00081926Novartis Pharmaceuticals112
已完成
3 期
Nilotinib ± Peg-IFN for First Line Chronic Phase CML PatientsChronic Myeloid LeukemiaNCT02201459Hospices Civils de Lyon200
已完成
2 期
A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CMLLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT02896842Versailles Hospital139
已完成
3 期
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)RSV InfectionNCT04938830Merck Sharp & Dohme LLC1,003